C12Y 304/21047
Alternative-complement-pathway c3/c5 convertase , i.e. properdin factor b
Official title: Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
C12Y304/21047 (Alternative-complement-pathway c3/c5 convertase , i.e. properdin factor b) appears on 23 US grants and 43 published applications in this corpus.
Search patents in C12Y- Granted patents
- 23
- Published applications
- 43
- Assignees
- 14
- Inventors
- 41
- Latest grant
- 23 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 2 |
| 2009 | 3 | 4 |
| 2010 | 1 | 3 |
| 2011 | 2 | 2 |
| 2012 | 2 | 3 |
| 2013 | 2 | 1 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 1 | 4 |
| 2017 | 2 | 2 |
| 2018 | 1 | 2 |
| 2019 | 3 | 2 |
| 2020 | 1 | 5 |
| 2021 | 2 | 0 |
| 2022 | 0 | 3 |
| 2023 | 1 | 3 |
| 2024 | 2 | 3 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Complement factor B (CFB) iRNA compositions and methods of use thereof23 Apr 2024US 11,965,166 B2Alnylam Pharmaceuticals, Inc.
- Modulators of Complement Factor B12 Mar 2024US 11,926,830 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating complement factor B expression22 Aug 2023US 11,732,265 B2Ionis Pharmaceuticals, Inc.
- Complement component iRNA compositions and methods of use thereof30 Nov 2021US 11,186,842 B2Alnylam Pharmaceuticals, Inc.
- Complement factor B analogs and their uses11 May 2021US 11,001,822 B2Wellstat ImmunoTherapeutics, LLC
- Compositions and Methods for Modulating Complement Factor B Expression22 Jan 2026US 2026/0022382 A1Ionis Pharmaceuticals, Inc.
- Complement factor b (cfb) irna compositions and methods of use thereof23 Jan 2025US 2025/0027080 A1Alnylam Pharmaceuticals, Inc.
- Complement component irna compositions and methods of use thereof14 Nov 2024US 2024/0376477 A1Alnylam Pharmaceuticals, Inc.
- Small interfering rna targeting cfb and uses thereof5 Sep 2024US 2024/0294916 A1
- Modulators of Complement Factor B25 Jul 2024US 2024/0247268 A1Ionis Pharmaceuticals, Inc.
Most cited
By later US patents
- siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)53US 7,612,196 B2Dharmacon, Inc. · 2009
- siRNA targeting inner centromere protein antigens (INCENP)52US 7,582,747 B2Dharmacon, Inc. · 2009
- siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)52US 7,592,442 B2Dharmacon, Inc. · 2009
- siRNA targeting nucleoporin 62kDa (Nup62)43US 7,691,998 B2Dharmacon, Inc. · 2010
- siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)16US 8,232,385 B2Dharmacon, Inc. · 2012